Eyevensys Announced Appointment Of Dr Violaine Desort-Henin As Clinical Director

Paris (France), 23rd February 2015 – Eyevensys, an innovative ophthalmic therapy company, announced the appointment Dr. Violaine Desort-Hénin as Clinical Director. In this position, Dr. Desort-Hénin will be responsible for overseeing the development of Eyevensys clinical development program.

Dr. Violaine Desort-Hénin commented:

"Joining such an innovative company at this stage is an amazing challenge which I am thrilled to face alongside the team. Eyevensys innovative technology will push the present limits of ocular treatments and revolutionize patient's lives. It is a genuinely exciting moment in any company's life when workbench developments are translated into clinics, and I am proud to be on board!"

Dr. Violaine Desort-Hénin combines several competences, from vet medicine and surgery to toxicology and clinical trial management, particularly in the area of ophthalmology. Various professional experiences have enabled her to acquire a translational medical expertise and a deep understanding of the complex physiopathology underlying ocular diseases. She was previously Head of Preclinical and Clinical Development in a listed biotech company for over 5 years. During her previous tenure, she participated in all phases of development up to clinical Phase III and participated in the design of strategic international programs.

"We welcome Violaine Desort-Hénin to our senior management team. Dr. Desort-Henin brings solid and innovative clinical and regulatory expertise as well as a successful track record that will help accelerate the development of our lead program in Uveitis at a crucial juncture for the Company," said Eyevensys' CEO, Raffy Kazandjian.

For more information, please contact:
Raffy Kazandjian, CEO
[email protected]
Tel: +33-184 791 060

About Eyevensys :

Eyevensys was founded in 2009 by Dr. Francine Behar-Cohen, Professor of Ophthalmology at the Descartes school of medicine in Paris, and Chief Medical Director of the Gonin Ophthalmic Hospital in Lausanne. The Company developed a novel therapeutic approach based on the electroporation into the ciliary muscle of plasmids encoding therapeutic proteins. This leads to the expression of such proteins in ocular tissues over extended periods. www.eyevensys.com

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.